ZEPP vs. DBD, PAR, VYX, EVLV, ATEN, CRSR, SSYS, CTLP, MITK, and ALLT
Should you be buying Zepp Health stock or one of its competitors? The main competitors of Zepp Health include Diebold Nixdorf (DBD), PAR Technology (PAR), NCR Voyix (VYX), Evolv Technologies (EVLV), A10 Networks (ATEN), Corsair Gaming (CRSR), Stratasys (SSYS), Cantaloupe (CTLP), Mitek Systems (MITK), and Allot (ALLT). These companies are all part of the "computer hardware" industry.
Zepp Health vs. Its Competitors
Zepp Health (NYSE:ZEPP) and Diebold Nixdorf (NYSE:DBD) are both computer hardware companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.
52.6% of Zepp Health shares are held by institutional investors. Comparatively, 97.0% of Diebold Nixdorf shares are held by institutional investors. 36.0% of Zepp Health shares are held by company insiders. Comparatively, 0.3% of Diebold Nixdorf shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Diebold Nixdorf had 6 more articles in the media than Zepp Health. MarketBeat recorded 10 mentions for Diebold Nixdorf and 4 mentions for Zepp Health. Diebold Nixdorf's average media sentiment score of 0.88 beat Zepp Health's score of 0.61 indicating that Diebold Nixdorf is being referred to more favorably in the news media.
Zepp Health has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Diebold Nixdorf has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500.
Zepp Health presently has a consensus target price of $60.23, suggesting a potential upside of 54.91%. Diebold Nixdorf has a consensus target price of $75.00, suggesting a potential upside of 19.27%. Given Zepp Health's higher probable upside, equities research analysts clearly believe Zepp Health is more favorable than Diebold Nixdorf.
Diebold Nixdorf has a net margin of -0.35% compared to Zepp Health's net margin of -38.81%. Diebold Nixdorf's return on equity of 7.92% beat Zepp Health's return on equity.
Diebold Nixdorf has higher revenue and earnings than Zepp Health. Diebold Nixdorf is trading at a lower price-to-earnings ratio than Zepp Health, indicating that it is currently the more affordable of the two stocks.
Summary
Diebold Nixdorf beats Zepp Health on 13 of the 17 factors compared between the two stocks.
Get Zepp Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZEPP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ZEPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zepp Health Competitors List
Related Companies and Tools
This page (NYSE:ZEPP) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access